Image Credits: Neurocrine Biosciences
Neurocrine Biosciences Inc. confirms that it will showcase the new data from the phase 2 SAVITRI study of osavampator in adults with crucial depressive disorder at the Psych Congress 2025, conducted in San Diego on September 17-21. The results will be disclosed on 18th September from 4:30 pm – 5:45 pm PT in the form of a poster presentation titled ‘latest discoveries and emerging trends in MDD.’ Osavampator (NBI-1065845) is a selective investigational positive allosteric modulator of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA-PAM) in established as a capable adjunctive treatment for adults with major depressive disorder (MDD) who experience a deficient response to the oral antidepressant treatment.
Regarding the announced top-line data from the phase 2 SAVITRI study, Neurocrine has also worked on the phase 3 registrational program of osavampator in January 2025. The program consists of five studies that are currently active under enrollment. For additional detailed information regarding phase 3 osavampator studies, visit ClinicalTrials.gov.
MD, chief medical officer of Neurocrine Biosciences, Sanjay Keswani said, “The extensive data that we will reveal at Psych Congress from our phase 2 SAVITRI study is a valuable step forward in identifying and addressing crucial depressive disorder. We are confident enough in our osavampator program and its capabilities to stand as a first-in-class treatment.”
The posters highlight the functional impact of MDD on patients in their daily lives and a selective positive allosteric modulator of the AMPA receptor in the development of MDD treatment. It will also elaborate statistically prominent and clinically justified improvements in depression, as well as tolerability in MDD adults. Poster 152 will include information about the once-daily valbenazine that enhanced the symptoms and impacts of tardive dyskinesia with or without a psychiatric diagnosis. Poster 84 is about mental, socioemotional, and physical functional enhancement following valbenazine treatment for tardive dyskinesia.
Poster 108 will be based on an interview and a qualitative study of caregiver, prescriber, and patient positioning of functional outcome improvements in schizophrenia. Poster 150 highlights how valbenazine improves tardive dyskinesia in patients with or without race or ethnicity: post HOC analyses of extended data from the KINECT 4 study. Poster 98 shows estimation of the longitudinal change and minimal clinically important difference (MCID) in the Tardive Dyskinesia Impact Scale (TDIS), a proven patient-reported outcome measure, tardive dyskinesia-specific.
Rushikesh Mane, Master of Science, is a healthcare sector expert who delivers insightful and impactful news for Towards Healthcare, focusing on industry developments, policy updates, and scientific innovations.
